) --

Jazz Pharmaceuticals



) hit a new 52-week high Friday as it is currently trading at $40.13, above its previous 52-week high of $39.08 with 561,061 shares traded as of 10:26 a.m. ET. Average volume has been 735,000 shares over the past 30 days.

Jazz has a market cap of $1.4 billion and is part of the

health care

sector and


industry. Shares are up 79.2% year to date as of the close of trading on Thursday.

Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes products for neurology and psychiatry primarily in the United States. The company has a P/E ratio of 27.8, below the average drugs industry P/E ratio of 28.7 and above the S&P 500 P/E ratio of 17.7.

  • Practice your JAZZ trading strategies and win cash in our stock game.

TheStreet Ratings rates Jazz as a


. The company's strengths can be seen in multiple areas, such as its notable return on equity, robust revenue growth, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. You can view the full

Jazz Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center